STAT3 and neoplasm: In this study, the biocompatibility of the drug was also reported in a mouse tumor bearing model.57 An aptamer-decorated hypoxia-responsive nanoparticles (DGL)n@Apt co-loading with gemcitabine monophosphate and STAT3 inhibitor HJC0152 was developed to evaluate its tumor penetration in pancreatic ductal adenocarcinoma cells.